Japan’s RaQualia, Once Pfizer’s Nagoya Unit, Plans To Go Public
This article was originally published in PharmAsia News
Executive Summary
RaQualia Pharma, which until July 1 was the Japanese Nagoya Laboratories research unit of U.S. drug maker Pfizer, expects to go public by early 2011, thanks to a major investment by NIF SMBC Ventures. Those funds have given RaQualia enough to last for as long as five years, or past the time it is scheduled to go public. The company was formed by Nagoya personnel, and some of its drug candidates are being supplied to Pfizer. RaQualia President Atsushi Nagahisa said the 70 researchers from the former Pfizer unit pulled together to form the new company after failing to convince the U.S. firm not to close the operation. (Click here for more - a subscription may be required